Beta radiation in lesions > 15 mm: a START subgroup

Area of Science:

• Cardiology
• Interventional Cardiology
• Radiation Oncology

Background:

• In-stent restenosis after conventional treatment can reach 60% in long coronary lesions.
• The Stents and Radiation Therapy (START) trial investigated intracoronary beta radiation for restenosis.
• Recurrent in-stent restenosis poses a significant clinical challenge, especially in complex lesion subsets.

Purpose of the Study:

• To evaluate the efficacy of intracoronary beta radiation using a 30 mm Strontium-90/Yttrium-90 source train.
• To assess treatment outcomes in patients with long coronary lesions (> 15 mm).
• To determine the impact of beta radiation on major adverse cardiac events and revascularization rates.

Main Methods:

• A subgroup analysis of the START trial included 239 patients with long coronary lesions.
• Patients received either an intracoronary beta radiation catheter (n=128) or a placebo (n=111).
• Clinical and angiographic parameters were assessed at 8-month follow-up.

Main Results:

• Radiation therapy group showed a significant reduction in major adverse cardiac events (16.4% vs 29.7%).
• Target vessel revascularization (14.8% vs 28.8%) and target lesion revascularization (11.7% vs 27.9%) were significantly lower in the radiation group.
• Binary restenosis rates were significantly reduced with beta radiation, with no observed stent thrombosis.

Conclusions:

• Intracoronary beta radiation effectively prevents early recurrent restenosis in long coronary lesions.
• Further research is needed to confirm long-term efficacy and durability of the treatment effect.
• Beta radiation therapy represents a potential therapeutic option for complex coronary lesion management.